Amneal Pharmaceuticals, Inc.
AMRX
$6.82
$0.071.04%
| Weiss Ratings | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.35 | |||
| Price History | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 5.41% | |||
| 30-Day Total Return | 13.67% | |||
| 60-Day Total Return | 17.59% | |||
| 90-Day Total Return | 23.77% | |||
| Year to Date Total Return | 14.05% | |||
| 1-Year Total Return | 203.11% | |||
| 2-Year Total Return | 95.98% | |||
| 3-Year Total Return | 19.44% | |||
| 5-Year Total Return | -17.43% | |||
| 52-Week High % Change | -2.29% | |||
| 52-Week Low % Change | 237.62% | |||
| Price | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.98 | |||
| 52-Week Low Price | $2.02 | |||
| 52-Week Low Price (Date) | May 18, 2023 | |||
| 52-Week High Price (Date) | May 15, 2024 | |||
| Valuation | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.11B | |||
| Enterprise Value | 4.85B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.57 | |||
| Earnings Per Share Growth | -37.04% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.84 | |||
| Price/Book (Q) | -33.03 | |||
| Enterprise Value/Revenue (TTM) | 1.94 | |||
| Price | $6.82 | |||
| Enterprise Value/EBITDA (TTM) | 8.88 | |||
| Enterprise Value/EBIT | 15.17 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 307.28M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 908 947 3120 | |||
| Address | 400 Crossing Boulevard Bridgewater, NJ 08807 | |||
| Website | amneal.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 12.80% | |||
| Profit Margin | -6.76% | |||
| Management Effectiveness | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.64% | |||
| Return on Equity | -- | |||
| Income Statement | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.50B | |||
| Total Revenue (TTM) | 2.50B | |||
| Revenue Per Share | $8.12 | |||
| Gross Profit (TTM) | 924.40M | |||
| EBITDA (TTM) | 546.36M | |||
| EBIT (TTM) | 319.59M | |||
| Net Income (TTM) | -168.69M | |||
| Net Income Avl. to Common (TTM) | -168.69M | |||
| Total Revenue Growth (Q YOY) | 18.23% | |||
| Earnings Growth (Q YOY) | -709.17% | |||
| EPS Diluted (TTM) | -0.57 | |||
| EPS Diluted Growth (Q YOY) | -500.00% | |||
| Balance Sheet | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 48.46M | |||
| Cash Per Share (Q) | $0.16 | |||
| Total Current Assets (Q) | 1.38B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -16.61M | |||
| Current Ratio (Q) | 1.654 | |||
| Book Value Per Share (Q) | -$0.21 | |||
| Total Assets (Q) | 3.46B | |||
| Total Current Liabilities (Q) | 834.39M | |||
| Total Debt (Q) | 2.75B | |||
| Total Liabilities (Q) | 3.47B | |||
| Total Common Equity (Q) | -63.72M | |||
| Cash Flow | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -77.21M | |||
| Cash from Financing (TTM) | -222.83M | |||
| Net Change in Cash (TTM) | -99.45M | |||
| Levered Free Cash Flow (TTM) | 101.56M | |||
| Cash from Operations (TTM) | 201.46M | |||
